The effort we put in the last 2 years to properly measuring response to drugs is published in a paper in Nature Methods. Check out the GR metrics and how this approach solves some of the issues with large scale datasets: Nature Methods link (full text can be accessed here). This work is completed by a interactive website:...
The conference on Systems Approaches to Cancer Biology was a success with more than 90 participants and a lot of interesting talks. You can have a brief overview of the meeting in the Storify article based on the meeting from twitter posts.
We are in the process of writing a more formal meeting report. I will update as it comes together.
The Systems Approaches to Cancer Biology conference will take place April 3-6, 2016 at the Marine Biological Laboratory in Woods Hole, MA. This inaugural meeting co-sponsored by the NCI aims to bring together researchers applying systems methods to better understand cancer biology. We have 12 exciting speakers and we will select 18 speakers from submitted abstracts! Be sure to register: Website and ...
I am attending the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and presenting my two most recent projects with Mario Niepel. We have two posters on (1) the LINCS joint project (combined analysis of L1000 and phenotypical responses to kinase inhibitors) and (2) the GR metrics to quantify drug response. Please reach out if you want more information.
The manuscript co-authored by Melanie Adler and Susanne Ramm from the lab of Vishal Vaidya: "A quantitative approach to screen for kidney toxic compounds in vitro" has been accepted for publication in the Journal of the American Society of Nephrology. I am glad that my contribution for the analyses of transcriptional data helped the paper to be accepted in the top journal of nephrology. It demonstrates the strength of integrative and systematic approaches in pharmacology. I am looking forward to see the final version. Congrats to Melanie and Susie for their work!
We discuss how "Non‐genetic cell‐to‐cell variability results in fractional killing by TRAIL and therapeutic antibody agonists, limiting their effectiveness as anti‐cancer drugs. A simple model of initiator caspase dynamics reveals a threshold in caspase activity that separates dying and surviving cells."
The manuscript on TRAIL signaling co-authored with Jérémie Roux (Cell-to-cell variability in overcoming a caspase activity threshold and fractional killing by TRAIL) has been accepted at Molecular Systems Biology. Currently working on the final proof and the companion website. More to follow.